AbbVie was granted Breakthrough Therapy Designation (BTD) from the U.S. FDA for investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy.   The FDA’s BTD program is intended to expedite the development and review of medicines with preliminary...